Neuroscience Education Institute

09/17/2026

September is National Su***de Prevention Month. By increasing awareness and sharing evidence-based information, mental health professionals can help reduce stigma, recognize risk, and encourage timely support. Read more:

By increasing awareness and sharing evidence-based information, mental health professionals can help reduce stigma, recognize risk, and encourage timely support.

09/16/2026

The NEI team is here in New Orleans for Psych Congress 2026!! Stop by Booth 1441 in the Exhibit Hall to discover how NEI Membership can support your practice with trusted psychopharmacology education, hundreds of CME/CE opportunities, point-of-care prescribing guidance, clinical tools, patient education resources, and more. We look forward to connecting with you!

09/16/2026

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to DT120 (lysergide) orally disintegrating tablet (ODT) for major depressive disorder (MDD). Read more:

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to DT120 (lysergide) orally disintegrating tablet (ODT) for major depressive disorder (MDD).

09/16/2026

A better understanding of sleep can lead to better psychiatric care. Join us for the 2026 NEI Fall Congress Pre-Conference Workshop: Sleep, led by Thomas Schwartz, MD. Take a deeper dive into sleep-wake neurobiology, diagnostic strategies and practical, case-based approaches to treating sleep disorders.
Attend in person or join online via simulcast. Explore the agenda ➡️

Join the NEI Fall Congress Pre-Conference Sleep Workshop on Thursday, November 5, for expert-led education on diagnosing and treating sleep disorders in psychiatric practice.

09/15/2026

Lithium is a first-line treatment for bipolar disorder, but how might it affect long-term cardiovascular risk? A recent study examined whether lithium treatment was associated with the development of cardiovascular disease in adults with bipolar disorder. Read more:

09/12/2026

A recent study explored whether sodium-glucose cotransporter 2 (SGLT2) inhibitors may have neuroprotective potential and be associated with favorable psychiatric outcomes in older adults with mood and psychotic disorders. While the findings are promising, they do not establish causality, and prospective clinical trials are needed. Read more:

A recent study suggest that sodium-glucose cotransporter 2 (SGLT2) inhibitors may have neuroprotective potential and may be associated with favorable psychiatric outcomes in older adults with mood and psychotic disorders.

09/10/2026

Today is World Su***de Prevention Day. Awareness opens the conversation, and education strengthens our ability to respond. Through continued learning, mental health professionals can recognize changing risk, guide timely intervention, and help patients connect with care and hope.

Explore su***de prevention education and resources:

Education can play an important role in prevention. Increasing knowledge about su***de risk and warning signs can help reduce stigma, encourage open conversations, and empower families, schools, workplaces, and communities to connect at-risk individuals with professional evaluation and care

09/09/2026

In this episode, Dr. Andy Cutler and Dr. Tim Wilens explore the complex relationship between ADHD and substance use disorders, including diagnosis, treatment timing, medication selection, stimulant misuse and diversion, nonstimulant options, centanafadine’s abuse potential, and practical approaches to treatment monitoring. Listen now

In this episode, Dr. Andy Cutler speaks with Dr. Tim Wilens about the complex relationship between attention-deficit/hyperactivity disorder (ADHD) and substance use disorders. They discuss how to distinguish ADHD from substance-related cognitive symptoms, determine when co-occurring conditions shoul...

09/08/2026

In this edition of NEI Autocomplete, Dr. Andrew Cutler and Dr. Roger McIntyre answer some of the web’s most searched questions about selective serotonin reuptake inhibitors (SSRIs), including possible discontinuation symptoms, common side effects, treatment duration, and why medication changes should always be discussed with a health care professional.

Explore more expert answers about mental health and psychopharmacology in the full NEI Autocomplete playlist: https://nei.global/experts-answer

Evidence-based conversations should continue beyond the appointment. NEI’s Patient Education materials simplify complex topics to help patients stay informed and engaged in their treatment: https://nei.global/patiented

09/04/2026

When both a parent and young child have ADHD, could treating the parent strengthen behavioral intervention for the child? A randomized trial found that treating parental ADHD before behavioral parent training led to faster improvements in both parent and child clinical severity. Read more about the findings and implications for family-centered ADHD care:

Attention-deficit/hyperactivity disorder (ADHD) is highly heritable, and clinicians frequently encounter young children with ADHD whose parents also have ADHD symptoms that interfere with attending treatment, remembering behavioral plans, and practicing new skills consistently.